Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and beyond - A Comprehensive Review of the Current Literature

Journal of Urology

Volumn 195, Issue 2, 2016, Pages 254-263

  Oing, Christoph ^a   Rink, Michael ^a   Oechsle, Karin ^a   Seidel, Christoph ^a   Von Amsberg, Gunhild ^a   Bokemeyer, Carsten ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

carcinoma; drug therapy; salvage therapy; urinary bladder; urothelium

Indexed keywords

2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE; AFLIBERCEPT; ALPHA INTERFERON; ARSENIC TRIOXIDE; ATEZOLIZUMAB; BORTEZOMIB; CABAZITAXEL; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; INTERLEUKIN 2; IRINOTECAN; IXABEPILONE; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PEMBROLIZUMAB; PEMETREXED; PIRITREXIM; PLATINUM; PRALATREXATE; RAMUCIRUMAB; SATRAPLATIN; TOPOTECAN; UNINDEXED DRUG; VINFLUNINE; ANTINEOPLASTIC AGENT; BIOLOGICAL FACTOR; DEOXYCYTIDINE; PYRIMIDINE DERIVATIVE; SULFONAMIDE; VINBLASTINE;

ADVANCED CANCER; ADVANCED UROTHELIAL CARCINOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; HUMAN; MEDLINE; METASTATIC UROTHELIAL CARCINOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CARCINOMA, TRANSITIONAL CELL; PATHOLOGY; SALVAGE THERAPY; TUMOR RECURRENCE; URINARY BLADDER NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL FACTORS; CARBOPLATIN; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DEOXYCYTIDINE; HUMANS; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; PEMETREXED; PYRIMIDINES; SALVAGE THERAPY; SULFONAMIDES; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 84953837254     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2015.06.115     Document Type: Review

References (49)

1. J. Bellmunt, T.K. Choueiri, F.A. Schutz, and et al. Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and pitfalls Ann Oncol 22 2011 245
2. R. Dreicer Second-line chemotherapy for advanced urothelial cancer: because we should or because we can? J Clin Oncol 27 2009 4444
3. J. Bellmunt, C. Théodore, T. Demkov, and et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract J Clin Oncol 27 2009 4454
4. J.A. McCaffrey, S. Hilton, M. Mazumdar, and et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma J Clin Oncol 15 1997 1853
5. Y.S. Kim, M.K. Choi, J.Y. Hong, and et al. A phase II trial of weekly docetaxel for second-line treatment of urothelial carcinoma J Clin Oncol 31 suppl. 2013 abstract e15613
6. F. Joly, N. Tchen, C. Chevreau, and et al. Clinical benefit of second-line weekly paclitaxel in advanced urothelial carcinoma (AUC): A GETUG phase II study J Clin Oncol 22 suppl. 2004 abstract 4619
7. D. Papamichael, C.J. Gallagher, R.T. Oliver, and et al. Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter Br J Cancer 75 1997 606
8. D.J. Vaughn, C.M. Broome, M. Hussain, and et al. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer J Clin Oncol 20 2002 937
9. Y.J. Ko, C.M. Canil, S.D. Mukherjee, and et al. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study Lancet Oncol 14 2013 769
10. J.L. Lee, J.H. Ahn, S.H. Park, and et al. Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum Invest New Drugs 30 2012 1984
11. J.H. Hoffman-Censits, D.J. Vaiughn, J. Lin, and et al. A phase II study of cabazitaxel in patients with urothelial carcinoma who have disease progression following platinum-based chemotherapy J Clin Oncol 32 suppl. 2014 abstract e15519
12. A. Peer, A. Neumann, D. Keizman, and et al. A single-arm, multicenter, open-label phase II trial of cabazitaxel as second-line treatment for patients with locally advanced or metastatic transitional call carcinoma J Clin Oncol 33 suppl. 2015 abstract 372
13. H. Akaza, S. Naito, M. Usami, and et al. Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after cisplatin-containing therapy: a Japanese experience Jpn J Clin Oncol 37 2007 201
14. P. Albers, R. Siener, M. Härtlein, and et al. Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life Onkologie 25 2002 47
15. V. Gebbia, A. Testa, N. Borsellino, and et al. Single agent 2',2'-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a phase II study Clin Ter 150 1999 11
16. C.J. Sweeney, B.J. Roth, F.F. Kabbinavar, and et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium J Clin Oncol 24 2006 3451
17. M.D. Galsky, S. Mironov, A. Iasonos, and et al. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma Invest New Drugs 25 2007 265
18. R.M. Bambury, D.J. Benjamin, J.L. Chaim, and et al. The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience Oncologist 20 2015 508
19. S. Culine, C. Theodore, M. De Santis, and et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen Br J Cancer 94 2006 1395
20. D.J. Vaughn, S. Srinivas, W.M. Stadler, and et al. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study Cancer 115 2009 4110
21. J. Bellmunt, R. Fougeray, J.E. Rosenberg, and et al. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy Ann Oncol 24 2013 1466
22. T. Takahashi, S. Higashi, H. Nishiyama, and et al. Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen Jpn J Clin Oncol 36 2006 104
23. K. Matsumoto, A. Irie, T. Satoh, and et al. Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma Int J Urol 14 2007 1000
24. G. Fechner, R. Siener, M. Reimann, and et al. Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99) Int J Clin Pract 60 2006 27
25. T. Suyama, T. Ueda, S. Fukasawa, and et al. Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma Jpn J Clin Oncol 39 2009 244
26. K. Kanai, E. Kikuchi, T. Ohigashi, and et al. Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy Int J Clin Oncol 13 2008 510
27. P. Albers, S.I. Park, G. Niegisch, and et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99] Ann Oncol 22 2011 288
28. T. Otto, A. Bex, S. Krege, and et al. Paclitaxel-based second-line therapy for patients with advanced chemotherapy-resistant bladder carcinoma (M1): a clinical Phase II study Cancer 80 1997 465
29. T. Kouno, M. Ando, K. Yonemori, and et al. Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen Eur Urol 52 2007 1115
30. M. Bachner, and M. De Santis Second-line therapy in bladder cancer Curr Opin Urol 19 2009 533
31. K.S. Han, J.Y. Joung, T.S. Kim, and et al. Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy Br J Cancer 98 2008 86
32. J. Edeline, Y. Loriot, S. Culine, and et al. Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen Eur J Cancer 48 2012 1141
33. J.H. Lee, S.G. Kang, S.T. Kim, and et al. Modified MVAC as a second-line treatment for patients with metastatic urothelial carcinoma after failure of gemcitabine and cisplatin treatment Cancer Res Treat 46 2014 172
34. J. Kattan, S. Culine, C. Théodore, and et al. Second-line M-VAC therapy in patients previously treated with the M-VAC regimen for metastatic urothelial cancer Ann Oncol 4 1993 793
35. Cancer Genome Atlas Research Network Comprehensive molecular characterization of urothelial bladder carcinoma Nature 507 2014 315
36. G. Iyer, A.J. Hanrahan, M.I. Milowsky, and et al. Genome sequencing identifies a basis for everolimus sensitivity Science 338 2012 221
37. T. Powles, J.P. Eder, G.D. Fine, and et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Nature 515 2014 558
38. E.R. Plimack, S. Gupta, J. Bellmunt, and et al. A phase 1b study of pembrolizumab (Pembro; MK-3475) in patients (Pts) with advanced urothelial tract cancer Ann Oncol 25 suppl. 2014 abstract LBA23
39. A. Necchi, L. Mariani, N. Zaffaroni, and et al. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial Lancet Oncol 13 2012 810
40. R. Pili, R. Qin, P.J. Flynn, and et al. A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer Clin Genitourin Cancer 11 2013 477
41. S. Srinivas, S. Narayanan, L.C. Harshman, and et al. Phase II study of pazopanib with weekly paclitaxel in refractory urothelial cancer J Clin Oncol 33 suppl. 2015 abstract 294
42. D.P. Petrylak, S.T. Tagawa, M. Kohli, and et al. Interim results of a randomized phase 2 study of docetaxel with ramucirumab versus docetaxel in second-line advanced or metastatic urothelial carcinoma J Clin Oncol 33 suppl. 2015 abstract 295
43. T.K. Choueiri, R.W. Ross, S. Jacobus, and et al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer J Clin Oncol 30 2012 507
44. Sequist LV, Cassier P, Varga A, et al. Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected solid tumors. Presented at annual meeting of American Association for Cancer Research, San Diego, California, April 5-9, 2014, abstract CT326.
45. M.I. Milowsky, C. Dittrich, I.D. Martinez, and et al. Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3 J Clin Oncol 31 suppl. 2013 abstract 255
46. Y.N. Wong, S. Litwin, D. Vaughn, and et al. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma J Clin Oncol 30 2012 3545
47. C. Wülfing, J.P. Machiels, D.J. Richel, and et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma Cancer 115 2009 2881
48. A. Soave, O. Engel, G. Von Amsberg, and et al. Management of advanced bladder cancer in the era of targeted therapies Minerva Urol Nefrol 67 2015 103
49. N. Agarwal, J. Bellmunt, B.L. Maughan, and et al. Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma Clin Genitourin Cancer 12 2014 130